Our founders’ insights and achievements

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Caixa Capital Risc is leading the largest operation in the biotech sector in Spain, with a €55 million financing round in Sanifit

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

NuMat Medtech secures a €530,000 round of investment

Minoryx Therapeutics raises €21.3M in Series B funding round

QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros